Page 51 - Read Online

Page 18 of 19 Matrone et al. J Cancer Metastasis Treat 2021;7:23 https://dx.doi.org/10.20517/2394-4722.2021.47

Treat Rev 2018;66:64-73. DOI PubMed
92. Cappagli V, Moriconi D, Bonadio AG, et al. Proteinuria is a late-onset adverse event in patients treated with cabozantinib. J
Endocrinol Invest 2021;44:95-103. DOI PubMed
93. Basolo A, Matrone A, Elisei R, Santini F. Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
Semin Cancer Biol 2021:S1044-579X(20)30268. DOI PubMed
94. Blevins DP, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor
therapy for thyroid cancer. Thyroid 2014;24:918-22. DOI PubMed PMC
95. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer
resistance to selective kinase inhibitors. Oncogene 2004;23:6056-63. DOI PubMed
96. Arao T, Matsumoto K, Furuta K, et al. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase
inhibitor in human vascular endothelial cells. Anticancer Res 2011;31:2787-96. PubMed
97. Liu X, Shen T, Mooers BHM, Hilberg F, Wu J. Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol
2018;175:3504-15. DOI PubMed PMC
98. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 2019;47:D941-7.
DOI PubMed PMC
99. Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic
medullary thyroid carcinomas. Br J Cancer 2009;100:1777-83. DOI PubMed PMC
100. Kohno T, Tabata J, Nakaoku T. REToma: a cancer subtype with a shared driver oncogene. Carcinogenesis 2020;41:123-9. DOI
PubMed
101. Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol
2018;29:1869-76. DOI PubMed PMC
102. Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov 2018;8:836-
49. DOI PubMed
103. Seoane J, Capdevila J. The right compound for the right target: tackling RET. Ann Oncol 2018;29:1623-5. DOI PubMed
104. Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven
malignancies. J Thorac Oncol 2020;15:541-9. DOI PubMed PMC
105. Subbiah V, Shen T, Terzyan SS, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-
gatekeeper RET mutations. Ann Oncol 2021;32:261-8. DOI PubMed PMC
106. Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-
small-cell lung cancer. Ann Oncol 2020;31:1725-33. DOI PubMed
107. Rosen EY, Johnson ML, Clifford SE, et al. Overcoming MET-dependent resistance to selective RET inhibition in patients with RET
fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res 2021;27:34-42. DOI PubMed PMC
108. Drilon AE, Zhai D, Rogers E, et al. The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven
cancer models. J Clin Oncol 2020;38:3616. DOI
109. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol
2010;22:697-706. DOI PubMed PMC
110. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.
Nat Cell Biol 2014;16:717-27. DOI PubMed PMC
111. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell
2012;21:309-22. DOI PubMed
112. Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book
2016;35:298-308. DOI PubMed
113. Cunha LL, Marcello MA, Morari EC, et al. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.
Endocr Relat Cancer 2013;20:103-10. DOI PubMed
114. Bastman JJ, Serracino HS, Zhu Y, et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and
anaplastic thyroid cancer. J Clin Endocrinol Metab 2016;101:2863-73. DOI PubMed PMC
115. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated
with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014;24:1385-93. DOI
PubMed PMC
116. Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary
thyroid cancer and its variants. Oncotarget 2016;7:32318-28. DOI PubMed PMC
117. Ahn S, Kim TH, Kim SW, et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 2017;24:97-
106. DOI PubMed
118. Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with
advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 2019;19:196. DOI PubMed PMC
119. Rocklin RE, Gagel R, Feldman Z, Tashjian AH Jr. Cellular immune responses in familial medullary thyroid carcinoma. N Engl J Med
1977;296:835-8. DOI PubMed
120. George JM, Williams MA, Almoney R, Sizemore G. Medullary carcinoma of the thyroid.cellular immune response to tumor antigen
in a heritable human cancer. Cancer 1975;36:1658-61. DOI PubMed
121. Bilusic M, Heery CR, Arlen PM, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-
expressing carcinoma. Cancer Immunol Immunother 2014;63:225-34. DOI PubMed PMC